1YBetter than half the group
Rank 32 of 63 funds
Return +18.58%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 32No. 1 is SCBGENOME(E) +62.13%
LH HEALTH INNOVATION FUND
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
LHHEALTH-DSSF invests through the master fund AB International Health Care Portfolio 96.78%
This fundLHHEALTH-DSSF
The fund that actually investsAB International Health Care PortfolioThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Johnson & Johnson JNJ9.43%
Eli Lilly and Co LLY9.14%Fact sheet checked on 27 Oct 2026 · Top 6 shown, the rest grouped as Other · per AllianceBernstein fact sheet
Over the past year it trailed half its group; there is no rank for a longer period yet
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | MAX |
|---|---|---|---|---|---|---|---|
| +12.25% | +2.29% | +3.09% | +9.97% | +10.43% | +18.03% | +18.58% | +15.86% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun |
|---|
Largest drawdown in the selected period −24.18% Previous peak 2 Sep 2024 (NAV 6.5465) → Trough 7 Aug 2025 (NAV 4.9635) · Not back to the previous peak as of 3 Nov 2026
Currently −1.16% from the peak NAV of 6.5465 (2 Sep 2024)
Over 1 year, LHHEALTH-DSSF returned 1.17 per unit of volatility, ranking 14 of 40 funds · The highest is FP HCARE-A (1.64)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศ (หรือ “กองทุนหลัก (Master fund)”) เฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิ โดยกองทุนหลักที่ไปลงทุน คือ กองทุน AB International Health Care Portfolio ในชนิดหน่วยลงทุน class I USD สกุลเงินดอลล่าร์สหรัฐฯ (USD)… Its largest holdings are Johnson & Johnson 9.49% · Eli Lilly & Co 9.16% · UnitedHealth Group, Inc 6.56% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 20 Nov 2023, its NAV has fallen as much as −24.18% from its peak.
Actual total expense ratio (TER) 2.16% a year, against a ceiling of 5.00%. Management fee 1.61%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
It has a dividend policy but has not paid any dividends yet
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until 14:00, sell orders until 14:00, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 80.26% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · LHHEALTH-DSSF: pays dividends, TER 2.16% · LHHEALTH-A: no dividends, TER 2.16% · LHHEALTH-ASSF: no dividends, TER 2.16% · LHHEALTH-D: pays dividends, TER 2.16% · LHHEALTH-E: no dividends, TER 2.16%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Merck & MRK
Unitedhealth Group UNH6.16%
Roche ROG5.15%
Novartis NOVN4.20%
AstraZeneca AZN.L3.72%
Vertex Pharmaceuticals VRTX3.66%
Gilead Sciences GILD3.61%
Bristol-Myers Squibb Co BMY2.80%An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Eli Lilly and Co LLYDiabetes and weight-loss drugs
Merck & MRKHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
Novartis NOVNHospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
Gilead Sciences GILDA US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Hospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (96.78% as of 30 Sep 2026) × each stock's weight in the master fund · fact sheet from AllianceBernstein · Illustrations are for explanation only, not individual stock recommendations
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +0.0 | +2.1 | −6.5 | −0.5 | +1.4 | +5.0 | +1.0 | +3.5 | −2.1 | +9.3 | −0.8 | · | +12.2* |
| 2025 | +4.6 | +1.0 | −2.4 | −2.5 | −4.6 | +0.7 | −4.3 | +3.2 | +1.6 | +3.1 | +6.6 | −1.4 | +5.1 |
| 2024 | +2.6 | +2.9 | +2.1 | −5.4 | +3.1 | +2.3 | +0.3 | +3.9 | −4.8 | −4.8 | −0.1 | −7.3 | −6.0 |
| 2023 | · | · | · | · | · | · | · | · | · | · | +0.6 | +3.8 | +4.4* |